# Elamipretide Barth syndrome study record updated

> ClinicalTrials.gov lists a recruiting Elamipretide study sponsored by Stealth BioTherapeutics Inc.

- Evidence object: `story:elamipretide-barth-syndrome-study-updated:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-07-13
- Source checked: 2026-07-22
- Published by PeptideScanner: 2026-07-22
- Story landing page: https://peptidescanner.com/stories/elamipretide-barth-syndrome-study-updated/
- JSON record: https://peptidescanner.com/evidence/v1/objects/elamipretide-barth-syndrome-study-updated-v1.json
- Content SHA-256: `40254a98bebcc0722b290543988272049b41ec52ba60c3d6ed581bce0dbec664`

## Claims and source pins

### Headline

Elamipretide Barth syndrome study record updated ([`ctg-nct07531251-v4`](#source-ctg-nct07531251-v4))

### Summary

ClinicalTrials.gov lists a recruiting Elamipretide study sponsored by Stealth BioTherapeutics Inc. ([`ctg-nct07531251-v4`](#source-ctg-nct07531251-v4))

### Paragraph 1

ClinicalTrials.gov lists the NCT07531251 record under Stealth BioTherapeutics Inc. Its overall recruitment status was shown as recruiting when PeptideScanner reviewed the record. ([`ctg-nct07531251-v4`](#source-ctg-nct07531251-v4))

### Paragraph 2

The registry shows 2026-07-13 as its latest posted update date. This update reports the registry record and does not establish safety, effectiveness, or a trial outcome. ([`ctg-nct07531251-v4`](#source-ctg-nct07531251-v4))

## Sources

<a id="source-ctg-nct07531251-v4"></a>
- **4TAZPower: Elamipretide in Participants With Barth Syndrome · record history version 4 · last update posted 2026-07-13** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07531251?a=4&tab=history) (`ctg-nct07531251-v4`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "Elamipretide Barth syndrome study record updated." Version 1, published 2026-07-22. https://peptidescanner.com/evidence/v1/objects/elamipretide-barth-syndrome-study-updated-v1.json SHA-256: 40254a98bebcc0722b290543988272049b41ec52ba60c3d6ed581bce0dbec664.